BioNTech, China's Fosun strikes deal to potentially supply 10 mln doses of Covid-19 vaccine
The two companies are also working jointly on the development and marketing of potential Covid-19 vaccine products based on BioNTech's mRNA technology platform in Mainland China, Hong Kong and Macau
FILE PHOTO: The headquarters of biopharmaceutical company BioNTech are seen in Mainz, Germany July 31, 2018. REUTERS/Ralph Orlowski
German drug developer BioNTech SE on Thursday announced a potential deal with Shanghai Fosun Pharmaceutical Group Co Ltd to supply 10 million doses of their Covid-19 vaccine candidate to Hong Kong and Macau.
The two companies are also working jointly on the development and marketing of potential Covid-19 vaccine products based on BioNTech's mRNA technology platform in Mainland China, Hong Kong and Macau.
Keep updated, follow The Business Standard's Google news channel
